Endo Launches First Generic Version of Amgen’s RAVICTI, Expanding Access for Rare Disease Patients

Endo Launches First Generic Version of Amgen’s RAVICTI, Expanding Access for Rare Disease Patients

MALVERN, PA — Endo, a wholly-owned subsidiary of Mallinckrodt plc, has introduced the first and only FDA-approved generic version of Amgen’s RAVICTI® (glycerol phenylbutyrate) oral liquid in the United States, marking a significant step in broadening treatment access for patients with urea cycle disorders (UCDs). The generic 1.1 gm/mL oral liquid, approved through the U.S. Food and Drug Administration’s Abbreviated New Drug Application process, …